Loading...
Ursodeoxycholate inhibits mast cell activation and reverses biliary injury and fibrosis in Mdr2(−/−) mice and human primary sclerosing cholangitis
BACKGROUND AND AIM: Ursodeoxycholic acid (UDCA) is used to treat biliary disorders; and, bile acids alter mast cell (MC) histamine release. MCs infiltrate Mdr2(−/−) mice liver (model of Primary Sclerosing Cholangitis (PSC)). MC-derived histamine increases inflammation, hepatic stellate cell (HSC) ac...
Saved in:
| Published in: | Lab Invest |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
2018
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6214746/ https://ncbi.nlm.nih.gov/pubmed/30143751 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41374-018-0101-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|